Dr Ian M Frayling was a Consultant in Genetic Pathology, based at Cardiff & Vale University. He served on InSiGHT Council 2015-2024 and is a member of the Variant Interpretation Committee. He has a longstanding track record in all forms of hereditary GI and related Cancers. Dr Frayling was instrumental in introducing tumour testing into clinical practice, including the UK National External Quality Assessment Service for immunohistochemistry of MMR proteins. He led a major UK health-economic analysis and was Chief Investigator on an Australian MRC-funded project on systematic testing of cancers to find LS.